TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34506606
Drug: Oscillating protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oscillating protein diet (OP, 125 and 173 g/kg CP diets oscillated at 2‐d intervals)
Study: 34506606
Drug: Static protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Static protein diet (SP, 149 g/kg CP)
Study: 32791692
Drug: Intranasal phototherapy
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal phototherapy for 20 minutes, 3 times a week for 4 weeks
Study: 32711440
Drug: Oral glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral glutamine (400 mg/kg body weight per day)
Study: 33748833
Drug: High-dose influenza
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose influenza vaccine
Study: 33748833
Drug: Standard-dose influenza
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose influenza vaccine
Study: 34544820
Drug: Ofatumumab (1.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofatumumab (1.50 mg/1.73 m2)
Study: 33121452
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose clopidogrel (150 mg per day) + aspirin (100 mg per day) over 21 days
Study: 33121452
Drug: Normal dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal dose clopidogrel (75 mg per day) + aspirin (100 mg per day) over 21 days
Study: 33121452
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose clopidogrel + aspirin
Study: 33121452
Drug: Normal dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal dose clopidogrel + aspirin
Study: 36223114
Drug: iTBS plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: iTBS plus D‐cycloserine (100 mg)
Study: 32441467
Drug: Chlortetracycline hydrochloride
Normalized name: Chlortetracycline Hydrochloride
DrugBank: Chlortetracycline (DB09093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlortetracycline hydrochloride ointment (Control)
Study: 34854987
Drug: RCT (Root
Approvals — FDA: no, EMA: no, PMDA: no
Description: RCT (Root Canal Therapy)
Study: 36264378
Drug: Pembrolizumab-chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab-chemotherapy
Study: 35381576
Drug: Cetuximab-chemotherapy
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab-chemotherapy
Study: 32717127
Drug: Structured teaching
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured teaching module including intensive prophylactic measures administered by a trained oncology nurse
Study: 32717127
Drug: Standard information
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard information on HFS care administered by treating clinician (control)
Study: 34935407
Drug: Dabigatran vs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran vs Warfarin
Study: 34953525
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (abiraterone acetate 1000 mg daily + prednisolone 5 mg daily)
Study: 34953525
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (abiraterone acetate + prednisolone + enzalutamide 160 mg daily)
Study: 34953525
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (abiraterone acetate + prednisolone)
Study: 34478577
Drug: Low-dose anfibatide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose anfibatide (2 IU/60 kg)
Study: 34478577
Drug: Moderate-dose anfibatide
Normalized name: Anfibatide
DrugBank: Anfibatide (DB15094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-dose anfibatide (3 IU/60 kg)
Study: 34478577
Drug: High-dose anfibatide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose anfibatide (5 IU/60 kg)
Study: 33407774
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone (40 mg)
Study: 34292203
Drug: Sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 100 mg per day
Study: 33652129
Drug: Blinded acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinded acetaminophen
Study: 33652129
Drug: Blinded ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Blinded ibuprofen
Study: 33652129
Drug: Control (OTC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (OTC medications)
Study: 34877813
Drug: Edoxaban 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban 75 mg
Study: 32207274
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir administered according to the 3-0-3 titration algorithm (G3)
Study: 32207274
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir administered according to the 2-4-6-8 titration algorithm (G2)
Study: 33301990
Drug: MOCHA Standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOCHA Standard intervention (10-week program including small group discussions, health topic classes, and 60-min aerobic exercise twice a week)
Study: 32147440
Drug: Aggressive local
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive local treatment (surgery) for oligometastatic disease in gastric cancer
Study: 32717341
Drug: Implant placement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant placement in at least 1 eye
Study: 32717341
Drug: Infections requiring
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infections requiring a prescription
Study: 32717341
Drug: Initiation in
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initiation in IOP medication
Study: 33557924
Drug: Narrative enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrative enhancement and cognitive therapy (NECT)
Study: 32126028
Drug: Phacoemulsification without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phacoemulsification without ophthalmic viscosurgical devices (OVDs), using continuous irrigation mode and chopping technique.
Study: 32455866
Drug: soy milk
Normalized name: DIMETHICONE 4 g in 100 g CUTANEOUS PATCH [FERMENTED SOY MILK WRINKLE CARE SLEEPING MASK]
Approvals — FDA: no, EMA: no, PMDA: no
Description: soy milk + PS (1.6 g/day)
Study: 33113535
Drug: LI-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: LI-guided therapy
Study: 32978540
Drug: General verbal
Approvals — FDA: no, EMA: no, PMDA: no
Description: General verbal instructions on orthodontic treatment
Study: 33838870
Drug: Insulin (20–40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (20–40 mU/m2 per minute) and lipid (Intralipid) infusion
Study: 34333391
Drug: Milk and
Normalized name: Suave Gentle Body Wash Milk and Honey
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk and rapeseed protein (35 g per day, ratio 54:46 or 30:70)
Study: 34333391
Drug: Milk protein
Normalized name: Milk protein
DrugBank: Casein (DB10516)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk protein alone (35 g per day)
Study: 32067218
Drug: Metformin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin therapy for 6 months
Study: 32067218
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (women with PCOS without metformin)
Study: 35608580
Drug: Metformin 850
Normalized name: metFORMIN 850 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 850 mg orally twice a day (n = 1824)
Study: 35608580
Drug: Placebo orally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo orally twice a day (n = 1825)
Study: 32130058
Drug: Sinetrol‐XPur (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinetrol‐XPur (450 mg per tablet, 2 tablets once a day)
Study: 32130058
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 tablets once a day)
Study: 36014789
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg sodium butyrate twice a day (group A)
Study: 32409838
Drug: Cefazolin added
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefazolin added to anesthetics (Group G)
Study: 32409838
Drug: Conventional drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional drug group (Group C)
Study: 34341520
Drug: Vosoritide (15.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vosoritide (15.0 μg/kg/day)
Study: 34341520
Drug: Vosoritide (15.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vosoritide (15.0 μg/kg/day) after crossover from placebo
Study: 33923532
Drug: Probiotic mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic mixture containing Bifidobacterium animalis subsp. Lactis BB12 and Enterococcus faecium L3, administered daily for 3 months before allergen exposure
Study: 32507490
Drug: Intranasal lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal lidocaine administration
Study: 33989286
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (twice a week from the 21st day of life till discharge)
Study: 33291535
Drug: CHO_M (CHO–electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO_M (CHO–electrolyte solution + MBI)
Study: 33291535
Drug: Control (non‐carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (non‐carbohydrate solution + travelling introduction audio)
Study: 33291535
Drug: CHO (CHO–electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO (CHO–electrolyte solution + travelling introduction audio)
Study: 33823373
Drug: Compression force
Normalized name: Clean Force
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Compression force <82.5 N for CC
Study: 33626250
Drug: BNT162b2 mRNA
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 mRNA vaccine (first dose, days 14-20)
Study: 33626250
Drug: BNT162b2 mRNA
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 mRNA vaccine (second dose, 7 or more days after)
Study: 32819929
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of tranexamic acid (TXA) 1g, intravenous injection 3 hours postsurgery
Study: 32819929
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of tranexamic acid (TXA) 1g, intravenous injection at 3, 6, and 12 hours postsurgery
Study: 32491923
Drug: Rectal 200
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal 200 mcg misoprostol
Study: 32491923
Drug: Rectal 20
Normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal 20 mg hyoscine‐n‐butyl bromide
Study: 33446284
Drug: Yohimbine (alpha2-adrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine (alpha2-adrenergic antagonist)
Study: 32056820
Drug: 30-minute music
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-minute music therapy during colonoscopy
Study: 35120199
Drug: Canagliflozin (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canagliflozin (two doses)
Study: 35262569
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (HCQ) 800 mg on day 1 and 400 mg from day 2 to day 7
Study: 35381848
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL rapeseed oil per day (RO)
Study: 35381848
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL sunflower oil per day (SO)
Study: 32127178
Drug: Nonopioid-based analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonopioid-based analgesia (acetaminophen and ibuprofen)
Study: 33098434
Drug: n-3 fatty
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 fatty acids (1 g/day)
Study: 34109697
Drug: 10‐mg ulipristal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10‐mg ulipristal acetate (UPA) once daily for three 12‐week courses
Study: 32681739
Drug: Decitabine 10
Normalized name: cedazuridine-decitabine 100 mg-35 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decitabine 10 mg/m2 daily for 10 days plus dasatinib 100 mg daily
Study: 32681739
Drug: Decitabine 20
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine 20 mg/m2 daily for 10 days plus dasatinib 100 mg daily
Study: 32681739
Drug: Decitabine 10
Normalized name: cedazuridine-decitabine 100 mg-35 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decitabine 10 mg/m2 or 20 mg/m2 daily for 10 days plus dasatinib 140 mg daily (target dose)
Study: 33503302
Drug: Triple-component single-pill
Normalized name: Triple Wormer Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-component single-pill combination (olmesartan/amlodipine/hydrochlorothiazide 20/5/12.5 mg)
Study: 33503302
Drug: Equivalent two-pill
Normalized name: Two-Dyne Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equivalent two-pill regimen (olmesartan/hydrochlorothiazide 20/12.5 mg + amlodipine 5 mg)
Study: 33272946
Drug: 2.8 mg
Normalized name: pectin 2.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.8 mg folic acid
Study: 33272946
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg folic acid
Study: 34962559
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (120,000 IU of cholecalciferol monthly)
Study: 32037556
Drug: Web-based survey
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based survey assessing willingness to donate tissues for regenerative therapy
Study: 32037556
Drug: Increased familiarity
Normalized name: Canis lupus familiaris skin
DrugBank: Canis lupus familiaris skin (DB10409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased familiarity with regenerative medicine through a brief paragraph of information
Study: 34482306
Drug: Customized sound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Customized sound therapy with tinnitus sound matching (group A)
Study: 34482306
Drug: Customized sound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Customized sound therapy without tinnitus sound matching (group B)
Study: 32045406
Drug: Prolotherapy (PrT)
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolotherapy (PrT) injections
Study: 32021173
Drug: NSB drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSB drug capsules along with the standard of care treatment (Arm B)
Study: 32021173
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care treatment (Arm A)
Study: 34058888
Drug: 5% dextrose
Normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% dextrose solution
Study: 36251378
Drug: Individualized behavioral
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized behavioral intervention to reduce daily sedentary behavior by 1 hour
Study: 35789164
Drug: Topical calcipotriol
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical calcipotriol (0.005%) cream
Study: 33973806
Drug: Ferulic acid
Normalized name: Ferulic acid
DrugBank: Ferulic acid (DB07767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferulic acid (200 mg)
Study: 32295092
Drug: 4.5 g
Normalized name: Zosyn 4.5 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5 g of fructooligosaccharides + 2 g of maltodextrin (FOS group)
Study: 32295092
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of maltodextrin (placebo group)
Study: 35833597
Drug: Liraglutide (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (1.2 mg)
Study: 33217070
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU; n = 30)
Study: 32386744
Drug: Antimalarial drugs
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antimalarial drugs
Study: 32469305
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of acetylsalicylic acid (81 mg)
Study: 32469305
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of acetylsalicylic acid (Ecasil-81, 81 mg)
Study: 32469305
Drug: Food intake
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food intake during administration
Study: 616063739
Drug: Intermediate or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate or full doses of epirubicin-cyclophosphamide
Study: 34710105
Drug: Local-ingredients-based supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local-ingredients-based supplement (LIBS)
Study: 32366320
Drug: Mindfulness-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based cognitive therapy self-help (MBCT-SH)
Study: 32366320
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy self-help (CBT-SH)
Study: 35325665
Drug: Burst physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Burst physical therapy (two PT sessions weekly for 6 weeks)
Study: 35325665
Drug: Spaced physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spaced physical therapy (one PT session every 2 weeks for 6 months)
Study: 34377150
Drug: Naldemedine 0.2
Normalized name: naldemedine 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naldemedine 0.2 mg
Study: 35561315
Drug: Iptacopan 25
Normalized name: Iptacopan
DrugBank: Iptacopan (DB16200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iptacopan 25 mg for 4 weeks followed by 100 mg for up to 2 years (cohort 1)
Study: 35561315
Drug: Iptacopan 50
Normalized name: Iptacopan
DrugBank: Iptacopan (DB16200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iptacopan 50 mg for 4 weeks followed by 200 mg for up to 2 years (cohort 2)
Study: 33177265
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received treatment for BPSD.
Study: 32764111
Drug: Oral corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral corticosteroids (OCS)
Study: 38299639
Drug: Antimalarial therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimalarial therapy
Study: 33888139
Drug: Ceftolozane-tazobactam 3
Normalized name: ceftolozane / tazobactam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftolozane-tazobactam 3 g every 8 hours
Study: 35403225
Drug: Senicapoc (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Senicapoc (50 mg enteral) administered as soon as possible after randomization and again after 24 hours.
Study: 35403225
Drug: Senicapoc (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Senicapoc (50 mg enteral).
Study: 36285404
Drug: Targeted oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted oral naltrexone (50 mg) with weekly counseling for 12 weeks
Study: 34045905
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg WDTE60N capsule (150 mg curcuminoids)
Study: 35212740
Drug: High-protein and
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein and fiber-based multi-ingredient nutritional shake (HPF) (17 g protein, 6 g fiber)
Study: 35212740
Drug: Low-protein, lower
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein, lower fiber-based placebo (LPF) (1 g protein, 3 g fiber)
Study: 35318120
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist protocol with high LH levels on day six
Study: 35318120
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist protocol with low LH levels on day six
Study: 35318120
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist protocol with medium LH levels on day six
Study: 36273991
Drug: Per-oral pancreatoscopy-guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Per-oral pancreatoscopy-guided lithotripsy (POP)
Study: 35405168
Drug: BNT (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT (15 μg)
Study: 32772737
Drug: Oral medications
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral medications (including voltage‐gated calcium channels antagonists, voltage‐gated sodium channel antagonists, serotonin‐norepinephrine reuptake inhibitors, NMDA antagonists)
Study: 37349498
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg/Paracetamol 1000 mg
Study: 37349498
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg/Paracetamol 1000 mg/Codeine 60 mg
Study: 37349498
Drug: Paracetamol 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 1000 mg/Codeine 60 mg
Study: 34097231
Drug: 10 days
Normalized name: AlleRx 10-day Dose Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 days of antibiotic therapy
Study: 36501014
Drug: l-arginine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-arginine plus vitamin C